# Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)

> **NCT02286258** · PHASE1,PHASE2 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 166 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Kidney Diseases

## Interventions

- **DRUG:** Calcium EDTA
- **DRUG:** Gd-DOTA

## Key facts

- **NCT ID:** NCT02286258
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** The study was suspended after a suspected unexpected serious adverse event.
- **Last updated:** 2018-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02286258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02286258, "Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02286258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*